Manthana Laichapis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Manthana Laichapis has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Charkkrit Hongthong
Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, Thailand
2 shared publications - Khunjira Udomaksorn
Department of Pharmacy Administration, Faculty of Pharmaceutical Sciences, Prince of Songkla University, Songkla, 90110, Thailand
2 shared publications - Nusaraporn Kessomboon
Department of Social and Administrative Pharmacy, Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand
2 shared publications - Osot Nerapusee
School of Pharmacy, Eastern Asia University, Pathum Thani, Thailand
2 shared publications - Rungpetch Sakulbumrungsil
Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand
2 shared publications - Sitanun Poonpolsub
Food and Drug Administration Thailand, Nonthaburi, Thailand
2 shared publications
Latest Publications
- Open Access
- 1 July 2025
- Published by JMIR Publications Inc. in JMIRx Med
- Vol. 6, e65978
Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study
Background: Thailand’s pharmaceutical industry is prioritizing innovation and self-reliance through the development of incrementally modified drugs (IMDs), particularly sustained-release dosage forms. However, the financial feasibility of IMD development remains underexplored. Objective: This study evaluates the financial feasibility of developing sustained-release IMDs in Thailand, focusing on costs, timelines, and investment requirements to inform strategic decision-making. Methods: A mixed methods approach was used, combining literature reviews, expert interviews, and financial modeling. Two scenarios were analyzed: (1) only development (phase I) and (2) full clinical trials (phase I to III). Sensitivity analysis was used to assess the impact of key variables on financial feasibility. Results: The research and development (R&D) process for sustained-release IMDs takes 7 years for phase I–only development, costing US $1.46‐3.09 million, and 11 years for full clinical trials, costing US $18.60‐20.23 million. Process validation batches accounted for 60% of costs in phase I–only scenarios, while clinical trials represented 70% of costs in full clinical trial scenarios. The annual income required for a 5-year payback period ranged from US $0.20‐1.80 million (phase I only) to US $3.01‐27.11 million (full trials). Shorter R&D durations and longer payback periods substantially improved feasibility. Conclusions: Developing sustained-release IMDs in Thailand involves substantial costs and extended timelines but offers a lower-risk alternative to new chemical entities. Strategic investments, efficient R&D processes, and supportive policies are essential to enhance feasibility and alignment with national goals of innovation and self-reliance.
- 1 July 2025
- Published by JMIR Publications Inc. in JMIRx Med
- Vol. 6, e65978
Open AccessFinancial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study
Background: Thailand’s pharmaceutical industry is prioritizing innovation and self-reliance through the development of incrementally modified drugs (IMDs), particularly sustained-release dosage forms. However, the financial feasibility of IMD development remains underexplored. Objective: This study evaluates the financial feasibility of developing sustained-release IMDs in Thailand, focusing on costs, timelines, and investment requirements to inform strategic decision-making. Methods: A mixed methods approach was used, combining literature reviews, expert interviews, and financial modeling. Two scenarios were analyzed: (1) only development (phase I) and (2) full clinical trials (phase I to III). Sensitivity analysis was used to assess the impact of key variables on financial feasibility. Results: The research and development (R&D) process for sustained-release IMDs takes 7 years for phase I–only development, costing US $1.46‐3.09 million, and 11 years for full clinical trials, costing US $18.60‐20.23 million. Process validation batches accounted for 60% of costs in phase I–only scenarios, while clinical trials represented 70% of costs in full clinical trial scenarios. The annual income required for a 5-year payback period ranged from US $0.20‐1.80 million (phase I only) to US $3.01‐27.11 million (full trials). Shorter R&D durations and longer payback periods substantially improved feasibility. Conclusions: Developing sustained-release IMDs in Thailand involves substantial costs and extended timelines but offers a lower-risk alternative to new chemical entities. Strategic investments, efficient R&D processes, and supportive policies are essential to enhance feasibility and alignment with national goals of innovation and self-reliance.
- Open Access
- 1 July 2025
- Published by JMIR Publications Inc. in JMIRx Med
- Vol. 6 (1) , e77623
Authors’ Response to Peer Reviews of “Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study”
This is the author(s)’ responses to peer review reports related to MS ID#65978
- 1 July 2025
- Published by JMIR Publications Inc. in JMIRx Med
- Vol. 6 (1) , e77623
Open AccessAuthors’ Response to Peer Reviews of “Financial Feasibility of Developing Sustained-Release Incrementally Modified Drugs in Thailand’s Pharmaceutical Industry: Mixed Methods Study”
This is the author(s)’ responses to peer review reports related to MS ID#65978